CompletedPhase 2NCT00994695

Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine

Studying Meningococcal meningitis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Armauer Hansen Research Institute, Ethiopia
Principal Investigator
Abraham Aseffa Aseffa, M.D, PhD
Senior Sientist,Deputy Director, AHRI
Intervention
Mencevax ACW Vaccine(biological)
Enrollment
412 target
Eligibility
2-29 years · All sexes
Timeline
2005 – 2007

Study locations (1)

Collaborators

World Health Organization · Addis Ababa University · London School of Hygiene and Tropical Medicine

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00994695 on ClinicalTrials.gov

Other trials for Meningococcal meningitis

Additional recruiting or active studies for the same condition.

See all trials for Meningococcal meningitis →

← Back to all trials